AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04058145
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab is thought to block a receptor called PD-1. This receptor usually acts as a brake to prevent the body's immune system from attacking cancer cells. The antibody removes the brake to allow parts of the body's immune system (usually T cells) to attack the tumor.
Trial: NCT03205501
Drug: IV-administation of EMI-137
RxNorm normalized name: Oil of peppermint
DrugBank: EMI-137 (DB19174)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
Trial: NCT02937506
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The intervention is to use propofol as anesthesia during a colonoscopy.
Trial: NCT03273192
Drug: Adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
Trial: NCT03686163
Drug: Nerve Growth Factors
RxNorm normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the experimental group patients will receive NGF 20ug/d intranasally for 2 weeks
Trial: NCT01142700
Drug: BMS-824393
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, 10 mg, once daily
Trial: NCT01142700
Drug: BMS-824393
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, 30 mg, once daily
Trial: NCT01142700
Drug: BMS-824393
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Capsule, Oral, 100 mg, once daily
Trial: NCT01142700
Drug: Peginterferon Alpha-2a
RxNorm normalized name: PEGINTERFERON ALPHA-2A 180MCG/ML INJ,1ML
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Syringe, subcutaneous 180 mcg/0.5 mL, weekly
Trial: NCT01142700
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
Trial: NCT01548092
Drug: Adipose-derived stem cells without expanded
RxNorm normalized name: Allogenic bone marrow-derived mesenchymal stem cells
DrugBank: Allogenic bone marrow-derived mesenchymal stem cells (DB18032)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
Trial: NCT03701126
Drug: Bupivacaine 0.25% Injectable Solution
RxNorm normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose 1ml /kg of patient body weight
Trial: NCT03975829
Drug: dabrafenib
RxNorm normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: dabrafenib oral, twice daily
Trial: NCT03975829
Drug: trametinib
RxNorm normalized name: Trametinib
DrugBank: Trametinib (DB08911)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: trametinib oral, once daily
Trial: NCT02838940
Drug: Cefazolin
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
Trial: NCT02853539
Drug: Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous injection of Denosumab
Trial: NCT01069796
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80 mg/m² weekly
Trial: NCT01069796
Drug: Bevacizumab
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 10 mg/kg d1 d15
Trial: NCT00704496
Drug: Pseudoephedrine
RxNorm normalized name: Pseudoephedrine
DrugBank: Pseudoephedrine (DB00852)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pseudoephedrine is a 240 mg PO per day
Trial: NCT00779467
Drug: Neostigmine
RxNorm normalized name: Neostigmine
DrugBank: Neostigmine (DB01400)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
Trial: NCT00779467
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00617123
Drug: Vorapaxar 2.5 mg
DrugBank: Vorapaxar (DB09030)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Vorapaxar 2.5 mg oral tablet
Trial: NCT02289898
Drug: Demcizumab
RxNorm normalized name: Demcizumab
DrugBank: Demcizumab (DB12734)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: administered intravenously
Trial: NCT02289898
Drug: gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administered intravenously
Trial: NCT02684760
Drug: PF-06651600
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
Trial: NCT00002862
Drug: perillyl alcohol
RxNorm normalized name: Perillyl alcohol
DrugBank: Perillyl alcohol (DB15289)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00304434
Drug: Oseltamivir
RxNorm normalized name: Oseltamivir
DrugBank: Oseltamivir (DB00198)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00304434
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04231864
Drug: Epacadostat
RxNorm normalized name: epacadostat
DrugBank: Epacadostat (DB11717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given orally (PO)
Trial: NCT03296813
Drug: Torsemide
RxNorm normalized name: Torsemide
DrugBank: Torasemide (DB00214)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loop diuretic
Trial: NCT03296813
Drug: Furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loop diuretic
Trial: NCT00676650
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mg BID, oral
Trial: NCT00676650
Drug: sunitinib
RxNorm normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 37.5 mg/day, oral, administered on a continuous daily dosing regimen
Trial: NCT00774241
Drug: bevacizumab [Avastin]
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg iv every 3 weeks
Trial: NCT00774241
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 75mg/m2 every 3 weeks for 18 weeks
Trial: NCT04262739
Drug: NYH817G and NYH100P
RxNorm normalized name: cytarabine and daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Subject will orally administer NYH817G (15 mg) and NYH100P (100 mg) during the cycles(21 days)
Trial: NCT02658435
Drug: Tafenoquine 150 mg
RxNorm normalized name: tafenoquine 150 MG
DrugBank: Tafenoquine (DB06608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
Trial: NCT01149434
Drug: JI-101
RxNorm normalized name: Ji Xue Cao Whole
DrugBank: Centella asiatica (DB14256)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
Trial: NCT01149434
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
Trial: NCT02697617
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone
Trial: NCT03476681
Drug: NEO-201 in combination with pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: NEO-201 will be given intravenously every 2 weeks in combination with pembrolizumab. In each cycle subjects will receive 3 doses of NEO 201 and one dose of pembrolizumab.
Trial: NCT01257581
Drug: tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen citrate capsules
Trial: NCT00381849
Drug: Sugar Pill (Placebo)
RxNorm normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will take 2 pills, 2 times a day for 6 weeks.
Trial: NCT02562287
Drug: Clozapine
RxNorm normalized name: Clozapine
DrugBank: Clozapine (DB00363)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
Trial: NCT02562287
Drug: Risperidone
RxNorm normalized name: Risperidone
DrugBank: Risperidone (DB00734)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Risperidone, in a flexible dosage
Trial: NCT02562287
Drug: Olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine, flexible dosage
Trial: NCT02562287
Drug: Quetiapine
RxNorm normalized name: Quetiapine
DrugBank: Quetiapine (DB01224)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quetiapine, flexible dosage
Trial: NCT05544656
Drug: Tolperisone Hydrochloride
RxNorm normalized name: Tolperisone hydrochloride
DrugBank: Tolperisone (DB06264)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolperisone Hydrochloride tablets of 150 mg, administered three times a day
Trial: NCT02937207
Drug: Xie Wu Capsule
RxNorm normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experience formula of famous traditional Chinese professor Jianhua Hu
Trial: NCT02937207
Drug: Dan Ma Jia Tablet
RxNorm normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experience formula of famous traditional Chinese professor Xiaopu Xu
Trial: NCT02937207
Drug: Bu Shen Na Qi Granule
RxNorm normalized name: rabeprazole sodium Oral Granules
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Experience formula of famous traditional Chinese professor Changrong Shao
Trial: NCT01728740
Drug: Acarbose/Metformin FDC (BAY81-9783)
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
Trial: NCT01728740
Drug: Acarbose (Glucobay, BAYG5421)
RxNorm normalized name: Acarbose
DrugBank: Acarbose (DB00284)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
Trial: NCT01728740
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin 500mg, oral, single dose
Trial: NCT01504711
Drug: fosaprepitant dimeglumine
RxNorm normalized name: Fosaprepitant Dimeglumine
DrugBank: Fosaprepitant (DB06717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01765270
Drug: Saxagliptin
RxNorm normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: one 5-mg saxagliptin tablet daily
Trial: NCT00517192
Drug: Tipranavir
RxNorm normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00517192
Drug: Darunavir
RxNorm normalized name: Darunavir
DrugBank: Darunavir (DB01264)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00517192
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT03547830
Drug: Plerixafor
RxNorm normalized name: Plerixafor
DrugBank: Plerixafor (DB06809)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Plerixafor for Conditioning before HSCT.
Trial: NCT03547830
Drug: Gcsf
RxNorm normalized name: GlycoPEG-GCSF
DrugBank: GlycoPEG-GCSF (DB06022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GCSF for Conditioning before HSCT.
Trial: NCT01704534
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
Trial: NCT03433703
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib capsules will be administered orally, once daily in continuous 28-day cycles.~Body weight (BW) ≥60 kilograms (kg) - Lenvatinib 12 mg (taken as three 4-mg capsules); BW \<60 kg - Lenvatinib 8 mg (taken as two 4-mg capsules)
Trial: NCT01957150
Drug: Fluticasone Furoate/Vilanterol
RxNorm normalized name: fluticasone furoate/vilanterol 100/25 MCG/INHAL Dry Powder Inhaler, 30 Blisters
DrugBank: Fluticasone furoate (DB08906)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
Trial: NCT01957150
Drug: Vilanterol
RxNorm normalized name: Vilanterol
DrugBank: Vilanterol (DB09082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
Trial: NCT01628549
Drug: 50 mg P005672-HCl
RxNorm normalized name: meclizine hydrochloride 50 MG
DrugBank: Meclizine (DB00737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P005672-HCl administered as an oral capsule(s) once daily
Trial: NCT04113616
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cytarabine is an anti-cancer chemotherapy drug taken via injection.
Trial: NCT04113616
Drug: Decitabine
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine is an anti-cancer chemotherapy drug taken via injection.
Trial: NCT03368391
Drug: tetracaine HCl and oxymetazoline HCL
RxNorm normalized name: oxymetazoline / tetracaine
DrugBank: Oxymetazoline (DB00935)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.4 mL HCl and oxymetazoline HCl administered intranasally
Trial: NCT02351167
Drug: Combination NRT (Nicotine patch, Nicotine lozenge)
RxNorm normalized name: nicotine Oral Lozenge
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02351167
Drug: Varenicline
RxNorm normalized name: Varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00162968
Drug: escitalopram
RxNorm normalized name: Escitalopram
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00547625
Drug: tadalafil
RxNorm normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
Trial: NCT02568280
Drug: Faster-acting insulin aspart
RxNorm normalized name: diphenhydramine
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Trial: NCT02568280
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
Trial: NCT03078257
Drug: tirofiban in PV
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day.
Trial: NCT03078257
Drug: tirofiban in IC
DrugBank: Tirofiban (DB00775)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg\*min for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.
Trial: NCT03078257
Drug: antiplatelet thrombolysin
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.~(clopidogrel 600 mg+ ASA 300 mg)x1 day.
Trial: NCT03078257
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
Trial: NCT03078257
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
Trial: NCT03078257
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
Trial: NCT00145561
Drug: Saquinavir and Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02406287
Drug: Netarsudil (AR-13324) Ophthalmic Solution
RxNorm normalized name: netarsudil Ophthalmic Product
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Topical ophthalmic solution
Trial: NCT02406287
Drug: Netarsudil (AR-13324) Ophthalmic Solution Placebo
RxNorm normalized name: netarsudil Ophthalmic Solution
DrugBank: Netarsudil (DB13931)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Ophthalmic solution once a day
Trial: NCT01341678
Drug: Lanthanum Carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diet will be supplemented with 1000mg at each meal
Trial: NCT00163969
Drug: ketamine
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02828566
Drug: IV ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
Trial: NCT03985046
Drug: Sintilimab plus Chemotherapy
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab will be administered intravenously, a fixed dose of 200 mg. Paclitaxel 135mg/m2, carboplatin AUC=5. Once every 3 weeks.
Trial: NCT02930941
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
Trial: NCT00133367
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
Trial: NCT00133367
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
Trial: NCT00133367
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given starting on day 5 after transplant until the subjects white blood cell count recovers.
Trial: NCT00133367
Drug: Antithymocyte globulin
RxNorm normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
Trial: NCT00133367
Drug: Thymoglobulin
RxNorm normalized name: Thymoglobulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
Trial: NCT00133367
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
Trial: NCT02930941
Drug: 0.9% Sodium Chloride
RxNorm normalized name: LMD with 0.9% Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
Trial: NCT00994539
Drug: morphine sulfate
RxNorm normalized name: Morphine Sulfate
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: morphine sulfate 15 mg and 30 mg tablets